TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03853148

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago
Description: Exercise program for strength and balance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago
Description: Exercise program for strength and balance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago
Description: Exercise program for strength and balance
Study: NCT04044859

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Description: Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
Study: NCT03853148

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gentle yogic breathing
Description: yogic breathing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gentle yogic breathing
Description: yogic breathing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Gentle yogic breathing
Description: yogic breathing
Study: NCT04101500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Ipratropium Bromide Solution(C1) for Inhalation
Description: The patient's condition and basic condition were the same in the experimental group and the control group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Compound Ipratropium Bromide Solution(C1) for Inhalation
Description: The patient's condition and basic condition were the same in the experimental group and the control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Sodium Chlolate and Aminophylline Tablets(C2)
Description: Applied only to the experimental group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Applied only to the control group.
Study: NCT00119067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anthrax Vaccine Adsorbed

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Study: NCT02424643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $20 Amazon.com gift card

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Altruistic Incentive
Description: A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard Incentive
Description: A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data.
Study: NCT03080753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphinkeeper
Description: Intersphincteric implants in the anal sphincter
Study: NCT03866902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Physical Activity Intervention
Description: Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: English for Second Language Intervention
Description: Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons.
Study: NCT02861079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2
Description: 10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGE2
Description: 10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
Study: NCT03052959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Intervention
Description: The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
Study: NCT02991677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise intervention
Description: Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: weekly contact by study staff with survivorship information offered not related to neuropathy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistive training
Description: Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
Study: NCT01612299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zortress® /Everolimus
Description: Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zortress® /Everolimus
Description: Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml.
Study: NCT03806712

Intervention type: OTHER
Intervention: multi method questionary (developped by De Rosa, in 1995 and 2014)
Description: questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Intervention type: OTHER
Intervention: multi method questionary (developped by De Rosa, in 1995 and 2014)
Description: questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Intervention type: OTHER
Intervention: multi method questionary (developped by De Rosa, in 1995 and 2014)
Description: questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
Study: NCT04622215

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICIQ questionnaire
Description: questionnaire
Study: NCT00807248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram placebo
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gaboxadol placebo
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gaboxadol placebo
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 20 mg
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaboxadol 5 mg
Description: Once daily before bedtime for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Description: Once daily before bedtime for 8 weeks
Study: NCT03944174

Intervention type: PROCEDURE
Intervention: Fixation of unstable pelvic fractures
Description: Percutaneous fixation of both iliac bones through the sacrum using one screw

Intervention type: PROCEDURE
Intervention: Fixation of unstable pelvic fractures
Description: Percutaneous fixation of both iliac bones through the sacrum using one screw
Study: NCT03614897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on guidelines for care of individuals at risk of falling
Study: NCT01123837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluid
Description: The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluid
Description: The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5LR or lactated ringers
Description: The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5LR or lactated ringers
Description: The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction.
Study: NCT01494935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Glycemic Diet
Description: NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
Study: NCT00771160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
Study: NCT01494935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Normal fat, normal fat diet
Study: NCT03140852

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind Over Matter; Healthy Bowels, Healthy Bladder
Description: This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind Over Matter; Healthy Bowels, Healthy Bladder
Description: This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
Study: NCT03269331

Intervention type: BEHAVIORAL
Intervention: CTEP EBP Immersion
Description: 36 continuing ed credits, virtual library access, collaboration with expert mentors
Study: NCT04145453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention genotype personalized nutritional recommendations
Description: Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group 1 personalized nutritional recommendations
Description: Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 2 general nutritional recommendations
Description: Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
Study: NCT00658021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subcutaneous injection, 5 µg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subcutaneous injection,10 µg, twice a day
Study: NCT04016961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAT - Dog
Description: therapy dog added to inpatient PT and OT session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU - No Dog
Description: PT and OT as usual without the addition of therapy dog
Study: NCT02936453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device implantation
Description: * Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator
Study: NCT03525925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03954990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 4 tablets
Study: NCT03496441

Intervention type: OTHER
Intervention: Fecal sample collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.

Intervention type: OTHER
Intervention: Fecal sample collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.

Intervention type: OTHER
Intervention: Fecal sample collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.

Intervention type: OTHER
Intervention: Fecal sample collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
Study: NCT03504397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Folinic acid will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folinic acid
Description: Folinic acid will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
Study: NCT03341819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Catheterization
Description: Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
Study: NCT00319982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator (double-blind allocation of study medication)
Study: NCT00463242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Either 25 mg or 50 mg agomelatine orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00788294

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given intravenously only once at dose of 10 mg
Study: NCT03974932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic.
Study: NCT00788294

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given subcutaneously only once at dose of 5 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: Drug solution given subcutaneously only once at dose of 10 mg.
Study: NCT03974932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic.
Study: NCT02594735

Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).